A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma.

Trial Profile

A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2012

At a glance

  • Drugs Beclometasone; Fluticasone propionate; Prednisolone; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jun 2012 Actual patient number is 15 as reported by ClinicalTrials.gov.
    • 24 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 24 Mar 2012 Actual end date (9 Jul 2010) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top